Reach Neuro

Executive Summary

Reach Neuro is an early-stage neurotechnology startup pioneering an implantable spinal cord stimulation system to restore upper limb function in chronic stroke survivors. Founded in 2021 and based in New York, the company targets the cervical spinal cord with personalized electrical stimulation aimed at 're-awakening' neural pathways to enable shoulder, arm, and hand movement. Their approach addresses a large unmet need: over 7 million stroke survivors in the US alone, many with permanent motor deficits. While still preclinical, Reach Neuro's technology has the potential to improve quality of life and reduce caregiver burden. The company has not disclosed funding rounds or partnerships, but its focus on a validated mechanism (spinal cord stimulation) and a clear patient population positions it for significant interest from investors and strategic partners. Key risks include regulatory hurdles, clinical validation, and competition from other neuromodulation and rehabilitation technologies. Overall, Reach Neuro represents a high-risk, high-reward opportunity in the neurotech space.

Upcoming Catalysts (preview)

• 2027First-in-Human Clinical Trial Initiation40% success
• Q4 2026FDA Breakthrough Device Designation60% success
• Q2 2026Series A Funding Round50% success